Catherine Schulte
Stock Analyst at Baird
(4.03)
# 524
Out of 5,149 analysts
148
Total ratings
56.35%
Success rate
10.08%
Average return
Main Sectors:
Stocks Rated by Catherine Schulte
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CAI Caris Life Sciences | Maintains: Outperform | $26 → $28 | $19.38 | +44.48% | 2 | Feb 27, 2026 | |
| GRAL GRAIL | Maintains: Outperform | $113 → $82 | $52.76 | +55.42% | 2 | Feb 20, 2026 | |
| TEM Tempus AI | Initiates: Outperform | $59 | $51.40 | +14.79% | 1 | Feb 17, 2026 | |
| GH Guardant Health | Initiates: Outperform | $120 | $93.30 | +28.62% | 1 | Feb 17, 2026 | |
| A Agilent Technologies | Maintains: Outperform | $142 → $165 | $119.04 | +38.61% | 18 | Nov 25, 2025 | |
| EXAS Exact Sciences | Maintains: Outperform | $72 → $88 | $103.37 | -14.87% | 15 | Nov 4, 2025 | |
| AVTR Avantor | Maintains: Outperform | $15 → $17 | $8.78 | +93.62% | 14 | Oct 24, 2025 | |
| MTD Mettler-Toledo International | Maintains: Neutral | $1,210 → $1,230 | $1,316.71 | -6.59% | 10 | Aug 4, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Outperform | $553 → $567 | $508.10 | +11.59% | 28 | Jul 24, 2025 | |
| DHR Danaher | Maintains: Outperform | $226 → $229 | $204.01 | +12.25% | 11 | Jul 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $2 | $3.69 | -45.80% | 6 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $41 | $47.65 | -14.06% | 4 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $88 → $68 | $56.99 | +19.32% | 11 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $38 | $27.57 | +37.83% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $33 | $46.65 | -29.26% | 3 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $335 → $281 | $129.56 | +116.89% | 7 | Sep 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $208 → $217 | $312.14 | -30.48% | 7 | Oct 30, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $20 | $207.04 | -90.34% | 1 | Jun 28, 2018 |
Caris Life Sciences
Feb 27, 2026
Maintains: Outperform
Price Target: $26 → $28
Current: $19.38
Upside: +44.48%
GRAIL
Feb 20, 2026
Maintains: Outperform
Price Target: $113 → $82
Current: $52.76
Upside: +55.42%
Tempus AI
Feb 17, 2026
Initiates: Outperform
Price Target: $59
Current: $51.40
Upside: +14.79%
Guardant Health
Feb 17, 2026
Initiates: Outperform
Price Target: $120
Current: $93.30
Upside: +28.62%
Agilent Technologies
Nov 25, 2025
Maintains: Outperform
Price Target: $142 → $165
Current: $119.04
Upside: +38.61%
Exact Sciences
Nov 4, 2025
Maintains: Outperform
Price Target: $72 → $88
Current: $103.37
Upside: -14.87%
Avantor
Oct 24, 2025
Maintains: Outperform
Price Target: $15 → $17
Current: $8.78
Upside: +93.62%
Mettler-Toledo International
Aug 4, 2025
Maintains: Neutral
Price Target: $1,210 → $1,230
Current: $1,316.71
Upside: -6.59%
Thermo Fisher Scientific
Jul 24, 2025
Maintains: Outperform
Price Target: $553 → $567
Current: $508.10
Upside: +11.59%
Danaher
Jul 23, 2025
Maintains: Outperform
Price Target: $226 → $229
Current: $204.01
Upside: +12.25%
May 13, 2025
Maintains: Neutral
Price Target: $3 → $2
Current: $3.69
Upside: -45.80%
Apr 21, 2025
Maintains: Neutral
Price Target: $40 → $41
Current: $47.65
Upside: -14.06%
Feb 19, 2025
Downgrades: Neutral
Price Target: $88 → $68
Current: $56.99
Upside: +19.32%
Mar 1, 2023
Maintains: Outperform
Price Target: $42 → $38
Current: $27.57
Upside: +37.83%
Nov 21, 2022
Maintains: Outperform
Price Target: $56 → $33
Current: $46.65
Upside: -29.26%
Sep 22, 2020
Maintains: Neutral
Price Target: $335 → $281
Current: $129.56
Upside: +116.89%
Oct 30, 2019
Maintains: Neutral
Price Target: $208 → $217
Current: $312.14
Upside: -30.48%
Jun 28, 2018
Maintains: Outperform
Price Target: $17 → $20
Current: $207.04
Upside: -90.34%